Trial Profile

An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary) ; Binimetinib (Primary) ; Cetuximab (Primary) ; Crizotinib (Primary) ; Dasatinib (Primary) ; Encorafenib (Primary) ; Everolimus (Primary) ; Gemcitabine (Primary) ; Idelalisib (Primary) ; Larotrectinib (Primary) ; Methotrexate (Primary) ; Palbociclib (Primary) ; Panobinostat (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Talazoparib (Primary) ; Trastuzumab (Primary) ; Venetoclax (Primary)
Indications Adenocarcinoma; Cancer metastases; Colon cancer; Colorectal cancer; Rectal cancer
Focus Pharmacogenomic; Therapeutic Use
Acronyms EVIDENT

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com